SEARCH | CONTACT Our Company Technology Our Pipeline Partnering News & Events Careers F-star develops novel bispecific antibodies directed at improving the treatment of serious diseases, with a focus in the area of immuno-oncology. F-star designs and develops bispecific antibody products to improve the treatment of cancer. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology™ offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products. MODULAR ANTIBODY TECHNOLOGY Our robust discovery engine lets us easily “mix-and-match” antibody components to create unique bispecific antibody products. PIPELINE F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as “2-in-1” drugs. NEWS & EVENTS 9 January 2014: F-star creates asset-centric unit 10 December 2013: F-star appoints Tolga Hassan as Chief Financial Officer 23 October 2013: F-star announces formation of new asset-centric vehicle, F-star Alpha Ltd, with €9.4m Series A investment OUR COMPANY Company Overview Management Investors Board Scientific Advisors TECHNOLOGY Overview About Bispecifics Modular Antibody Technology Fcab mAb2 IP OUR PIPELINE F-star Technology Advantage F-star Lead Programme Immuno-Oncology Antibody-Drug-Conjugates PARTNERING Opportunities Partners NEWS & EVENTS Press Releases F-star in the news Publications Media inquiries Presentations CAREERS